TriangleHEALTH PROFESSIONAL · SOURCE READING
Response to therapy
Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 13, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
CT, fluorine F 18-fludeoxyglucose (18F-FDG) PET, and MRI are used to monitor the effects of systemic therapy in patients with unresectable, metastatic, or recurrent disease.[34]
Source links and citations
A baseline PET should be performed before tyrosine kinase inhibitor (TKI) therapy in patients who will be monitored for response with 18F-FDG PET. PET imaging may detect the activity of imatinib in GISTs much earlier than CT imaging, with decreased tumor avidity detected as soon as 24 hours after the first dose. Thus, PET may be a useful diagnostic modality for the very early assessment of response to imatinib therapy and for detecting resistance to TKIs.[12]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice